AAX Biotech forms strategic collaboration with Oblique Therapeutics for therapeutic antibody development
Biotech company AAX Biotech, specializing in innovative technologies for improving antibody-based medicines, is collaborating with Oblique Therapeutics, a biotech company developing new antibody medicines for severe diseases. This strategic collaboration will leverage AAX Biotech's proprietary epitope mapping technology, Seqitope™, to accelerate the advancement of Oblique Therapeutics' programs.The collaboration will commence with AAX Biotech applying its cutting-edge Seqitope™ technology to characterize antibody candidates of Oblique Therapeutics’ pain program targeting TRPV1, providing